Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1920

Aug 12, 2019

FDA announces new policy framework for development of regenerative medicine products

Posted by in categories: biotech/medical, genetics, life extension, policy

Today the U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework — outlined in a suite of four guidance documents — builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products. Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. The suite of guidance documents also defines a risk-based framework for how the FDA intends to focus its enforcement actions against those products that raise potential significant safety concerns. This modern framework is intended to balance the agency’s commitment to safety with mechanisms to drive further advances in regenerative medicine so innovators can bring new, effective therapies to patients as quickly and safely as possible. The policy also delivers on important provisions of the 21st Century Cures Act.

We’re at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease. This is no longer the stuff of science fiction. This is the practical promise of modern applications of regenerative medicine.

Aug 12, 2019

Latest Treatments For Kidney Failure

Posted by in category: biotech/medical

Gene therapy and stem cells could treat Kidney Failure.

Aug 12, 2019

The Futurist New Deal podcast welcomes Paul Spiegel from the Board of Directors at Humanity+, also the Founder of Libertas Biomedical- in a discussion about best practices for making longer lifespans a reality

Posted by in categories: biotech/medical, life extension, transhumanism

Click on photo to start video.

Aug 12, 2019

Kizoo Announces Support for N-LIfT Cancer Immunotherapy

Posted by in category: biotech/medical

Kizoo, part of the Forever Healthy Foundation, has announced today that it will be supporting biotech company LIfT Biosciences, a company that focuses on creating a new generation of cancer therapies that use our own immune systems.

Turning our immune system into a cancer-fighting machine

Led by CEO Alex Blyth, LIfT Biosciences is developing a new type of cancer immunotherapy approach that uses neutrophils, a type of immune cell, to seek and destroy all types of solid tumors.

Aug 12, 2019

Self-repairing organs could save your life in a heartbeat

Posted by in categories: biotech/medical, neuroscience

Our cells are more malleable than we thought – and by transforming them inside the body, we can mend broken hearts or even degenerating brains from within.

Aug 12, 2019

We are happy to announce our support for LIfT Biosciences. LIfT is developing the world’s first cell therapy to destroy all solid tumors, irrespective of strain or mutation. The team lead by Alex Blyth is achieving this by building the world’s 1st cell bank of innately cancer-killing neutrophils. Congrats! kizoo.com/en

Posted by in category: biotech/medical

We are happy to announce our support for LIfT Biosciences. LIfT is developing the world’s first cell therapy to destroy all solid tumors, irrespective of strain or mutation.

The team lead by Alex Blyth is achieving this by building the world’s 1st cell bank of innately cancer-killing neutrophils. Congrats!

kizoo.com/en

Aug 11, 2019

Novel dual stem cell therapy improving cardiac regeneration

Posted by in category: biotech/medical

As a medical emergency caused by severe cardiovascular diseases, myocardial infarction (MI) can inflict permanent and life-threatening damage to the heart. A joint research team comprising scientists from City University of Hong Kong (CityU) has recently developed a multipronged approach for concurrently rejuvenating both the muscle cells and vascular systems of the heart by utilizing two types of stem cells. The findings give hope to develop a new treatment for repairing MI heart, as an alternative to the existing complex and risky heart transplant for seriously-ill patients.

MI is a fatal disorder caused by a shortage of coronary blood supply to the myocardium. It leads to permanent loss of (cardiomyocytes, CMs), and scar tissue formation, resulting in irreversible damage to or even heart failure. With limited therapeutic options for severe MI and advanced heart failure, a heart transplant is the last resort. But it is very risky, costly and subject to limited suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

Dr. Ban Kiwon, a stem cell biologist from Department of Biomedical Sciences at CityU, has been focusing on developing novel stem cell-based treatments for cardiac regeneration. “Heart is an organ composed of cardiac muscles and blood vessels, where vessels are essential to supply oxygen and energy to the muscles. Since both cardiac muscles and vasculatures would be severely damaged following MI, the therapeutic strategies should focus on comprehensive repair of both at the same time. But so far the strategies only focus on either one,” he explains.

Aug 11, 2019

Artificial Intelligence Based Approaches to Identify Molecular Determinants of Exceptional Health and Life Span-An Interdisciplinary Workshop at the National Institute on Aging

Posted by in categories: biotech/medical, genetics, life extension, robotics/AI

Artificial intelligence (AI) has emerged as a powerful approach for integrated analysis of the rapidly growing volume of multi-omics data, including many research and clinical tasks such as prediction of disease risk and identification of potential therapeutic targets. However, the potential for AI to facilitate the identification of factors contributing to human exceptional health and life span and their translation into novel interventions for enhancing health and life span has not yet been realized. As researchers on aging acquire large scale data both in human cohorts and model organisms, emerging opportunities exist for the application of AI approaches to untangle the complex physiologic process(es) that modulate health and life span. It is expected that efficient and novel data mining tools that could unravel molecular mechanisms and causal pathways associated with exceptional health and life span could accelerate the discovery of novel therapeutics for healthy aging. Keeping this in mind, the National Institute on Aging (NIA) convened an interdisciplinary workshop titled “Contributions of Artificial Intelligence to Research on Determinants and Modulation of Health Span and Life Span” in August 2018. The workshop involved experts in the fields of aging, comparative biology, cardiology, cancer, and computational science/AI who brainstormed ideas on how AI can be leveraged for the analyses of large-scale data sets from human epidemiological studies and animal/model organisms to close the current knowledge gaps in processes that drive exceptional life and health span. This report summarizes the discussions and recommendations from the workshop on future application of AI approaches to advance our understanding of human health and life span.

Aging is often described as the outcome of interactions among genetic, environmental and lifestyle factors with wide variation in life and health span between and within species (Newman and Murabito, 2013; Partridge et al., 2018; Singh et al., 2019). Exceptional life and health span represents an extreme phenotype characterized by exceptional survival (well-beyond average life expectancy), delayed onset of age-related diseases (before 80 years of age) (Pignolo, 2019) and/or preservation of good health/function relative to their peers (Perls et al., 2000, 2002; Kaeberlein, 2018). The identification of SNP associations with exceptional life and health span is a starting point for identifying targets for interventions that could potentially promote healthy human aging.

Aug 11, 2019

Human microbiome churns out thousands of tiny novel proteins

Posted by in categories: biotech/medical, health

Living healthier and longer can depend on probiotics more than we ever thought.


The bacteria in our gut make thousands of tiny, previously unidentified proteins that could shed light on human health and advance drug development, Stanford researchers have found.

Aug 11, 2019

Bioinformatic prediction of critical genes and pathways involved in longevity in Drosophila melanogaster

Posted by in categories: biotech/medical, genetics, life extension

The pursuit of longevity has been the goal of humanity since ancient times. Genetic alterations have been demonstrated to affect lifespan. As increasing numbers of pro-longevity genes and anti-longevity genes have been discovered in Drosophila, screening for functionally important genes among the large number of genes has become difficult. The aim of the present study was to explore critical genes and pathways affecting longevity in Drosophila melanogaster. In this study, 168 genes associated with longevity in D. melanogaster were collected from the Human Ageing Genomic Resources (HAGR) database. Network clustering analysis, network topological analysis, and pathway analysis were integrated to identify key genes and pathways. Quantitative real-time PCR (qRT-PCR) was applied to verify the expression of genes in representative pathways and of predicted genes derived from the gene–gene sub-network. Our results revealed that six key pathways might be associated with longevity, including the longevity-regulating pathway, the peroxisome pathway, the mTOR-signalling pathway, the FOXO-signalling pathway, the AGE-RAGE-signalling pathway in diabetic complications, and the TGF-beta-signalling pathway. Moreover, the results revealed that six key genes in representative pathways, including Cat, Ry, S6k, Sod, Tor, and Tsc1, and the predicted genes Jra, Kay, and Rheb exhibited significant expression changes in ageing D. melanogaster strain w1118 compared to young ones. Overall, our results revealed that six pathways and six key genes might play pivotal roles in regulating longevity, and three interacting genes might be implicated in longevity. The results will not only provide new insight into the mechanisms of longevity, but also provide novel ideas for network-based approaches for longevity-related research.